Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | GLA | P06280 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336282 | 0.85 | TSHR (0.47) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL3336897 | 0.73 | BAZ2B (0.47) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL3336866 | 0.72 | BAZ2B (0.49) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL3337719 | 0.72 | KDM4E (0.49) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL3336295 | 0.72 | ALDH1A1 (0.43) | TSHRKDM4EALDH1A1GAAGLA | |
| SCHEMBL7806682 | 0.72 | KDM4E (0.55) | TSHRKDM4EALDH1A1GAAGLA | |
| SCHEMBL20594715 | 0.72 | TSHR (0.54) | TSHRKDM4EALDH1A1GAAGLA | |
| SCHEMBL2208516 | 0.70 | KDM4E (0.41) | TSHRCA12CA2CA7CA9 | |
| SCHEMBL2010893 | 0.70 | KDM4E (0.53) | TSHRKDM4EALDH1A1GAAGLA | |
| SCHEMBL12854934 | 0.69 | RAB9A (0.56) | TSHRCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362038-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362038-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362038-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144789-A1 | 1-Isopropyl-2-Oxo-1,2-dihydropyridine-3-carboxamide Derivatives having 5-HT4 Receptor Agonistic Activity | KATO TOMOKI | 2010-06-10 | — | — | US | disclosed |
| US-20100144789-A1 | 1-Isopropyl-2-Oxo-1,2-dihydropyridine-3-carboxamide Derivatives having 5-HT4 Receptor Agonistic Activity | KATO TOMOKI | 2010-06-10 | — | — | US | disclosed |
| US-20100144789-A1 | 1-Isopropyl-2-Oxo-1,2-dihydropyridine-3-carboxamide Derivatives having 5-HT4 Receptor Agonistic Activity | KATO TOMOKI | 2010-06-10 | — | — | US | disclosed |
| US-7691881-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691881-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691881-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-11-27 | — | — | US | disclosed |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-11-27 | — | — | US | disclosed |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-11-27 | — | — | US | disclosed |
| EP-1713797-B1 | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1713797-B1 | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2005073222-A1 | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144789-A1 | 1-Isopropyl-2-Oxo-1,2-dihydropyridine-3-carboxamide Derivatives having 5-HT4 Receptor Agonistic Activity | HRH4, HRH2, GPR4 | TSHR 153/4885CA12 4540/4885CA1 3538/4885 |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | HRH4, HRH2, GPR4 | TSHR 153/4885CA12 4540/4885CA1 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.